Pasithea Therapeutics Corp KTTA:NASDAQ

RT Quote | USD
Last | 05/14/24 EDT
6.65UNCH (UNCH)
Volume
982
52 week range
5.25 - 17.40
Loading...
  • Open6.81
  • Day High6.89
  • Day Low6.65
  • Prev Close6.65
  • 52 Week High17.40
  • 52 Week High Date12/11/23
  • 52 Week Low5.25
  • 52 Week Low Date12/20/23

Key Stats

  • Market Cap6.932M
  • Shares Out1.04M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.78
  • YTD % Change-10.14

KEY STATS

  • Open6.81
  • Day High6.89
  • Day Low6.65
  • Prev Close6.65
  • 52 Week High17.40
  • 52 Week High Date12/11/23
  • 52 Week Low5.25
  • 52 Week Low Date12/20/23
  • Market Cap6.932M
  • Shares Out1.04M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.78
  • YTD % Change-10.14

RATIOS/PROFITABILITY

  • EPS (TTM)-12.83
  • P/E (TTM)-0.52
  • Fwd P/E (NTM)-9.64
  • EBITDA (TTM)-15.331M
  • ROE (TTM)-47.07%
  • Revenue (TTM)-
  • Gross Margin (TTM)100.54%
  • Net Margin (TTM)-6,478.41%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Pasithea Therapeutics Corp

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the...
Lawrence Steinman M.D.
Executive Chairman, Co-Founder
Tiago Marques
Chief Executive Officer, Director
Daniel Schneiderman
Chief Financial Officer
Address
1111 Lincoln Road
Miami Beach, FL
33139
United States